RxDoctor Payments Data

George Akinkuoye, NP

Psychiatric/Mental Health · Framingham, MANPI 1366796088

Payments from drug & device makers

$975in general payments, 2019–2025

Across 57 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$385
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$272
  • Vanda Pharmaceuticals Inc.$144
  • Supernus Pharmaceuticals, Inc.$132
  • Alkermes, Inc.$25
  • Lundbeck LLC$18

What the payments were for

  • Food & beverage$81584%
  • Education$16016%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$975 in reported general payments places this provider in the 75th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$34,525
Medicare patients
32
Services billed
439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl52$82,525
RexultiBrexpiprazole25$38,249
TrintellixVortioxetine Hydrobromide35$17,196
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine370$10,544
Clonazepam306$2,629
Hydroxyzine Pamoate171$1,970
Quetiapine Fumarate145$1,742
Gabapentin135$1,653
Prazosin Hcl72$1,391
Venlafaxine Hcl ErVenlafaxine Hcl24$1,342
Lamotrigine122$1,246
Methylphenidate Hcl41$1,173
Vilazodone Hcl16$1,114
Paroxetine Hcl79$1,102
Bupropion XlBupropion Hcl64$1,040

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$385$82,52552 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

Other psychiatric/mental health in Framingham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →